

April 16, 2010

**Hisamitsu Pharmaceutical Announces Marketing Approval of FENTOS® TAPE
(Development Code: HFT-290), Transdermal, Long-Acting Cancer Pain Relief Patch**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President and CEO: Hirotaka Nakatomi; hereinafter "Hisamitsu Pharmaceutical") got a marketing approval of FENTOS® TAPE (Development Code: HFT-290), a transdermal, long-acting cancer pain relief patch, on April 16, 2010, as it had applied for the approval in June 2008.

FENTOS® will be marketed jointly by Kyowa Hakko Kirin Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Yuzuru Matsuda) under the joint marketing agreement for Japan concluded in June 2008.

FENTOS® TAPE is a narcotic ethical(Rx) pharmaceutical product developed as a transdermal patch of fentanyl citrate, a synthetic narcotic that exhibits significant analgesic effects, using Hisamitsu Pharmaceutical's transdermal drug delivery system (TDDS).

This patch has drug release properties suitable for a single daily application. Since FENTOS® has a clinical advantage of allowing easier adherence to the basic principles of opioid analgesics ("by the clock") that require evaluation of pain and observation of the presence of adverse reactions every 24 hours, and scheduled administration at a predetermined time of the day, it is expected to exert stable and sustained analgesic effects.

Hisamitsu Pharmaceutical hopes to contribute to the improvement of quality of life in patients suffering from cancer pain by providing adequate and appropriate information about this drug.